Quantinno Capital Management LP Buys 96,605 Shares of Illumina, Inc. $ILMN

Quantinno Capital Management LP boosted its position in Illumina, Inc. (NASDAQ:ILMN) by 18.5% during the 1st quarter, HoldingsChannel.com reports. The firm owned 617,543 shares of the life sciences company’s stock after purchasing an additional 96,605 shares during the quarter. Quantinno Capital Management LP’s holdings in Illumina were worth $76,118,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Impact Partnership Wealth LLC raised its holdings in shares of Illumina by 235.8% in the 1st quarter. Impact Partnership Wealth LLC now owns 11,080 shares of the life sciences company’s stock valued at $1,366,000 after acquiring an additional 7,780 shares in the last quarter. Louisiana State Employees Retirement System purchased a new position in shares of Illumina during the first quarter worth about $5,460,000. SG Americas Securities LLC increased its position in shares of Illumina by 8.0% in the first quarter. SG Americas Securities LLC now owns 86,318 shares of the life sciences company’s stock worth $10,640,000 after purchasing an additional 6,425 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al increased its position in shares of Illumina by 27.4% in the fourth quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 348,011 shares of the life sciences company’s stock worth $45,645,000 after purchasing an additional 74,900 shares during the last quarter. Finally, New York State Teachers Retirement System raised its stake in Illumina by 2.7% in the fourth quarter. New York State Teachers Retirement System now owns 149,638 shares of the life sciences company’s stock valued at $19,627,000 after purchasing an additional 4,002 shares in the last quarter. 89.42% of the stock is owned by institutional investors.

Illumina Stock Up 1.9%

Shares of NASDAQ ILMN opened at $192.98 on Wednesday. Illumina, Inc. has a one year low of $88.00 and a one year high of $199.14. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36. The firm’s 50 day simple moving average is $173.22 and its two-hundred day simple moving average is $146.03. The stock has a market capitalization of $29.20 billion, a P/E ratio of 35.09, a PEG ratio of 2.80 and a beta of 1.47.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The firm had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same period in the previous year, the business posted $0.97 EPS. The business’s quarterly revenue was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, analysts expect that Illumina, Inc. will post 5.22 EPS for the current fiscal year.

Insider Buying and Selling

In other news, SVP Patricia Leckman sold 783 shares of the firm’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $162.59, for a total transaction of $127,307.97. Following the transaction, the senior vice president directly owned 21,259 shares of the company’s stock, valued at approximately $3,456,500.81. This trade represents a 3.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Scott M. Davies sold 615 shares of the firm’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $180.00, for a total value of $110,700.00. Following the transaction, the insider directly owned 20,953 shares in the company, valued at $3,771,540. This trade represents a 2.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,003,769 shares of company stock worth $155,710,908 over the last 90 days. Insiders own 2.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on ILMN shares. Piper Sandler lifted their target price on shares of Illumina from $170.00 to $200.00 and gave the company an “overweight” rating in a research report on Wednesday, July 1st. TD Cowen restated a “hold” rating on shares of Illumina in a research report on Wednesday, July 15th. JPMorgan Chase & Co. raised shares of Illumina from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $125.00 to $185.00 in a report on Wednesday, June 10th. Canaccord Genuity Group upped their target price on shares of Illumina from $140.00 to $190.00 and gave the stock a “hold” rating in a research report on Tuesday, July 14th. Finally, Wall Street Zen lowered shares of Illumina from a “buy” rating to a “hold” rating in a research report on Saturday, July 18th. Nine equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $156.88.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.